0L35 Stock Chart & Stats
$16.42
-$1.09(-6.61%)
At close: 4:00 PM EDT
$16.42
-$1.09(-6.61%)
Day’s Range― - ―
52-Week Range$14.35 - $25.34
Previous CloseN/A
Volume6.86K
Average Volume (3M)8.71K
Market Cap
$1.57B
Enterprise Value$2.15K
Total Cash (Recent Filing)$788.49M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)24.0
Beta1.56
Next Earnings
Nov 04, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding105,576,225
10 Day Avg. Volume5,874
30 Day Avg. Volume8,708
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.63Price Target Upside37.79% Upside
Rating ConsensusHold
Number of Analyst Covering17
EPS Forecast (FY)3.67
Revenue Forecast (FY)$1.83B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Durable PMO FranchiseSarepta’s PMO franchise delivers high gross margins and a large, adherent patient base, supporting durable product-level profitability. High adherence and >1,800 treated patients imply recurring dispensing and stable unit economics, underpinning sustainable cash conversion from core commercial operations.
Growing Collaboration And Contract Manufacturing RevenueMaterial and rising collaboration/manufacturing revenue diversifies cash sources beyond product sales. Roche-related manufacturing receipts and higher collaboration guidance create multi-year revenue visibility, reduce reliance on single-product demand cycles, and support funding of R&D and operations without immediate equity dilution.
Improved Liquidity And Operational DisciplineA near-billion cash position combined with meaningful H1 cash generation and deep OpEx cuts provides a multi-quarter runway. Sustained expense discipline that delivered GAAP/non‑GAAP operating income indicates management can fund pivotal trials and regulatory activities while moderating funding risk over the medium term.
Bears Say
Persistent Negative Operating And Free Cash FlowDespite recent cash balances, Sarepta has not achieved durable self‑funding: operating and free cash flows remain negative and volatile. Continued cash burn raises funding risk for late‑stage programs and commercialization investments absent sustained collaboration receipts or asset sales, constraining long‑term capital flexibility.
Declining Product Revenue And ELEVIDYS HeadwindsA steep YoY product revenue decline signals structural demand and conversion challenges for ELEVIDYS and core products. Management notes H2 product revenue below H1 and a ~6‑month enrollment‑to‑infusion lag, meaning commercial recovery is delayed and top‑line growth may remain muted through much of the next year.
Regulatory Delays And Clinical Holds Constrain Pipeline OptionalityClinical holds and delayed cohort readouts postpone regulatory pathways and shrink near‑term optionality for gene therapy programs. Program interruptions reduce the value of pipeline assets, delay potential label expansions or approvals, and prolong time to commercial return for high‑investment gene therapies.
Sarepta Therapeutics News
0L35 FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest share price was $14.35 and its highest was $25.34 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.57B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 89 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.217 by -$0.267.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Sarepta Therapeutics dividends here
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.16.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,576,225 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.217. Following the earnings report the stock price went up 2.141%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in GB:0L35
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.63 (37.79% Upside)
$22.63 (37.79% Upside)
Blogger Sentiment
Bullish
GB:0L35 Sentiment 69%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
0L35 Company Deck
0L35 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.View all GB:0L35 earnings summaries0L35 Stock 12 Month Forecast
Average Price Target
$22.63
▲(37.79% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―